<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GABAPENTIN - gabapentin tablet, film coated </strong><br>NorthStar Rx LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use gabapentin tablets, USP safely and effectively. See full prescribing information for gabapentin tablets, USP.<br><br>GABAPENTIN tablets USP, for oral use<br>Initial U.S. Approval: 1993<br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Gabapentin tablets, USP are indicated for: </p>
<ul class="Disc">
<li>Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> in adults (<a href="#Section_1">1</a>)</li>
<li>Adjunctive therapy in the treatment of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with and without secondary generalization, in adults and pediatric patients 3 years and older with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<a href="#Section_1">1</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Postherpetic Neuralgia (<a href="#Section_2.2">2.2</a>)    <ul class="Disc">
<li>Dose can be titrated up as needed to a dose of 1800 mg/day</li>
<li>Day 1: Single 300 mg dose</li>
<li>Day 2: 600 mg/day (i.e., 300 mg two times a day)</li>
<li>Day 3: 900 mg/day (i.e., 300 mg three times a day)</li>
</ul>
</li>
<li><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> with Partial Onset Seizures (<a href="#Section_2.3">2.3</a>)<ul class="Disc">
<li>Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily</li>
<li>Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days</li>
</ul>
</li>
<li>Dose should be adjusted in patients with reduced renal function (<a href="#Section_2.4">2.4</a>, <a href="#Section_2.5">2.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 600 mg, and 800 mg (<a href="#Section_3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to gabapentin or its ingredients (<a href="#Section_4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>): discontinue gabapentin if an alternative etiology cannot be established (<a href="#Section_5.1">5.1</a>)</li>
<li>Driving impairment: warn patients not to drive until they have gained sufficient experience with gabapentin to assess whether it will impair their ability to drive (<a href="#Section_5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>/Sedation and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>: Gabapentin may impair the patient’s ability to operate complex machinery (<a href="#Section_5.3">5.3</a>)</li>
<li>Increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency may occur in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders if gabapentin is abruptly discontinued (<a href="#Section_5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation: monitor for suicidal thoughts and behavior (<a href="#Section_5.5">5.5</a>)</li>
<li>Neuropsychiatric Adverse Reactions in Children 3 to 12 Years of Age: monitor for such events (<a href="#Section_5.6">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥8% and at least twice that for placebo) were: </p>
<ul class="Disc">
<li>Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (<a href="#Section_6.1">6.1</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> in patients &gt;12 years of age: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span> (<a href="#Section_6.1">6.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> in patients 3 to 12 years of age: <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> (<a href="#Section_6.1">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: based on animal data, may cause fetal harm (<a href="#Section_8.1">8.1</a>)</li>
<li>Pediatric Use: effectiveness as adjunctive therapy in treatment of <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> in pediatric patients below the age of 3 years has not been established (<a href="#Section_8.4">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Administration Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage for Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Dosage in Elderly</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Effects on Driving and Operating Heavy Machinery</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>/Sedation and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Withdrawal Precipitated <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status Epilepticus</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age)</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Tumorigenic Potential</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Sudden and Unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in Patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Other Antiepileptic Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Hydrocodone</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Morphine</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 MAALOX (aluminum hydroxide, magnesium hydroxide)</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></a></h2>
<h2><a href="#section-14.2" class="toc">14. 2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> for Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> (Adjunctive Therapy)</a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Gabapentin tablets, USP are indicated for:</p>
<ul class="Disc">
<li>Management of postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> in adults</li>
<li>Adjunctive therapy in the treatment of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with and without secondary generalization, in adults and pediatric patients 3 years and older with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Administration Information</h2>
<p class="First">Administer gabapentin tablets orally with or without food.<br><br>Inform patients that, should they break the scored 600 mg or 800 mg gabapentin tablet in order to administer a half-tablet, they should take the unused half-tablet as the next dose. Half-tablets not used within 28 days of breaking the scored tablet should be discarded.<br><br>If the gabapentin tablets dose is reduced, discontinued, or substituted with an alternative medication, this should be done gradually over a minimum of 1 week (a longer period may be needed at the discretion of the prescriber).</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage for Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></h2>
<p class="First">In adults with postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, gabapentin tablets may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). The dose can subsequently be titrated up as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief to a dose of 1800 mg/day (600 mg three times a day). In clinical studies, efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day with comparable effects across the dose range; however, in these clinical studies, the additional benefit of using doses greater than 1800 mg/day was not demonstrated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First"><span class="Underline">Patients 12 years of age and above<br></span><br>The starting dose is 300 mg three times a day. The recommended maintenance dose of gabapentin tablets is 300 mg to 600 mg three times a day. Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. Administer gabapentin tablets three times a day using 600 mg or 800 mg tablets. The maximum time between doses should not exceed 12 hours. <br><span class="Underline"><br>Pediatric Patients Age 3 to 11 years<br></span><br>The starting dose range is 10 mg/kg/day to 15 mg/kg/day, given in three divided doses, and the recommended maintenance dose reached by upward titration over a period of approximately 3 days. The recommended maintenance dose of gabapentin tablets in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses. The recommended maintenance dose of gabapentin tablets in patients 5 to 11 years of age is 25 mg/kg/day to 35 mg/kg/day, given in three divided doses. Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study. The maximum time interval between doses should not exceed 12 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosage Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage adjustment in patients 12 years of age and older with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or undergoing hemodialysis is recommended, as follows (see dosing recommendations above for effective doses in each indication):</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>TABLE 1. Gabapentin Tablets Dosage Based on Renal Function 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="7">TID = Three times a day; BID = Two times a day; QD = Single daily dose<br><span class="Sup">a</span>For patients with creatinine clearance &lt;15 mL/min, reduce daily dose in proportion to creatinine clearance (e.g., patients with a creatinine clearance of 7.5 mL/min should receive one-half the daily dose that patients with a creatinine clearance of 15 mL/min receive).<br><span class="Sup">b</span>Patients on hemodialysis should receive maintenance doses based on estimates of creatinine clearance as indicated in the upper portion of the table and a supplemental post-hemodialysis dose administered after each 4 hours of hemodialysis as indicated in the lower portion of the table.<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Renal Function Creatinine Clearance (mL/min)<br>
</td>
<td class="Rrule" valign="top">Total Daily <br>Dose Range <br>(mg/day)<br>
</td>
<td class="Rrule" colspan="5" valign="top">Dose Regimen <br>(mg)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">≥60<br>
</td>
<td class="Rrule" valign="top">900 to 3600<br>
</td>
<td class="Rrule" valign="top">300 TID<br>
</td>
<td class="Rrule" valign="top">400 TID<br>
</td>
<td class="Rrule" valign="top">600 TID<br>
</td>
<td class="Rrule" valign="top">800 TID<br>
</td>
<td class="Rrule" valign="top">1200 TID<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">&gt;30 to 59<br>
</td>
<td class="Rrule" valign="top">400 to 1400<br>
</td>
<td class="Rrule" valign="top">200 BID<br>
</td>
<td class="Rrule" valign="top">300 BID<br>
</td>
<td class="Rrule" valign="top">400 BID<br>
</td>
<td class="Rrule" valign="top">500 BID<br>
</td>
<td class="Rrule" valign="top">700 BID<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">&gt;15 to 29<br>
</td>
<td class="Rrule" valign="top">200 to 700<br>
</td>
<td class="Rrule" valign="top">200 QD<br>
</td>
<td class="Rrule" valign="top">300 QD<br>
</td>
<td class="Rrule" valign="top">400 QD<br>
</td>
<td class="Rrule" valign="top">500 QD<br>
</td>
<td class="Rrule" valign="top">700 QD<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">15<span class="Sup">a</span><br>
</td>
<td class="Rrule" valign="top">100 to 300<br>
</td>
<td class="Rrule" valign="top">100 QD<br>
</td>
<td class="Rrule" valign="top">125 QD<br>
</td>
<td class="Rrule" valign="top">150 QD<br>
</td>
<td class="Rrule" valign="top">200 QD<br>
</td>
<td class="Rrule" valign="top">300 QD<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"></td>
<td class="Rrule" colspan="5" valign="top">Post-Hemodialysis Supplemental Dose (mg)<span class="Sup">b</span><span class="Bold"></span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Hemodialysis<br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top">125<span class="Sup">b</span><br>
</td>
<td class="Rrule" valign="top">150<span class="Sup">b</span><br>
</td>
<td class="Rrule" valign="top">200<span class="Sup">b</span><br>
</td>
<td class="Rrule" valign="top">250<span class="Sup">b</span><br>
</td>
<td class="Rrule" valign="top">350<span class="Sup">b</span><br>
</td>
</tr>
</tbody>
</table>
<p>Creatinine clearance (CLCr) is difficult to measure in outpatients. In patients with stable renal function, creatinine clearance can be reasonably well estimated using the equation of Cockcroft and Gault:<br></p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a&amp;name=gabapentin-fig1.jpg"> </p>
<p><br>The use of gabapentin tablets in patients less than 12 years of age with compromised renal function has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Dosage in Elderly</h2>
<p class="First">Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li>600 mg: white, biconvex, elliptical, film-coated tablets,with deep break line on both sides and debossed with ‘D’ and ‘24’ on either side of the break line on one side and plain on other side.<span class="Bold"></span>
</li>
<li>800 mg: white, biconvex, elliptical, film-coated tablets,with deep break line on both sides and debossed with ‘D’ and ‘25’ on either side of the break line on one side and plain on other side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<br><p class="First">Gabapentin tablets are contraindicated in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or its ingredients.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS), also known as multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, has occurred with gabapentin. Some of these reactions have been fatal or life-threatening. DRESS typically, although not exclusively, presents with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and/or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, in association with other organ system involvement, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, hematological abnormalities, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, or <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> sometimes resembling an acute <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved.<br><br>It is important to note that early manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, may be present even though <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Gabapentin should be discontinued if an alternative etiology for the signs or symptoms cannot be established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Effects on Driving and Operating Heavy Machinery</h2>
<p class="First">Patients taking gabapentin should not drive until they have gained sufficient experience to assess whether gabapentin impairs their ability to drive. Driving performance studies conducted with a prodrug of gabapentin (gabapentin enacarbil tablet, extended release) indicate that gabapentin may cause significant driving impairment. Prescribers and patients should be aware that patients’ ability to assess their own driving competence, as well as their ability to assess the degree of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> caused by gabapentin, can be imperfect. The duration of driving impairment after starting therapy with gabapentin is unknown. Whether the impairment is related to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <span class="Italics">[see </span><span class="Italics"><span class="Italics"><a href="#Section_5.3">Warnings and Precautions (5.3)</a>] </span></span>or other effects of gabapentin is unknown.<br><br>Moreover, because gabapentin causes <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>]</span>, patients should be advised not to operate complex machinery until they have gained sufficient experience on gabapentin to assess whether gabapentin impairs their ability to perform such tasks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>/Sedation and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></h2>
<p class="First">During the controlled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials in patients older than 12 years of age receiving doses of gabapentin up to 1800 mg daily, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> were reported at a greater rate in patients receiving gabapentin compared to placebo: i.e., 19% in drug versus 9% in placebo for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, 17% in drug versus 7% in placebo for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and 13% in drug versus 6% in placebo for <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. In these trials <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> were common adverse reactions leading to discontinuation of gabapentin in patients older than 12 years of age, with 1.2%, 0.8% and 0.6% discontinuing for these events, respectively.<br><br>During the controlled trials in patients with post-herpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> were reported at a greater rate compared to placebo in patients receiving gabapentin, in dosages up to 3600 mg per day: i.e., 21% in gabapentin-treated patients versus 5% in placebo-treated patients for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and 28% in gabapentin-treated patients versus 8% in placebo-treated patients for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> were among the most common adverse reactions leading to discontinuation of gabapentin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Withdrawal Precipitated <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status Epilepticus</span></h2>
<p class="First">Antiepileptic drugs should not be abruptly discontinued because of the possibility of increasing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency.<br><br>In the placebo-controlled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> studies in patients &gt;12 years of age, the incidence of <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> in patients receiving gabapentin was 0.6% (3 of 543) vs. 0.5% in patients receiving placebo (2 of 378). Among the 2074 patients &gt;12 years of age treated with gabapentin across all <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> studies (controlled and uncontrolled), 31 (1.5%) had <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>. Of these, 14 patients had no prior history of <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> either before treatment or while on other medications. Because adequate historical data are not available, it is impossible to say whether or not treatment with gabapentin is associated with a higher or lower rate of <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> than would be expected to occur in a similar population not treated with gabapentin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</h2>
<p class="First">Antiepileptic drugs (AEDs), including gabapentin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p>
<br><p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<br><p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p>
<br><p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>TABLE 2 Risk by Indication for Antiepileptic Drugs in the Pooled Analysis 
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Indication<br>
</td>
<td class="Rrule" valign="top">Placebo Patients with Events Per 1000 Patients<br>
</td>
<td class="Rrule" valign="top">Drug Patients with Events Per 1000 Patients<br>
</td>
<td class="Rrule" valign="top">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients<br>
</td>
<td class="Rrule" valign="top">Risk Difference: Additional Drug Patients with Events Per 1000 Patients<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">3.4<br>
</td>
<td class="Rrule" align="center" valign="top">3.5<br>
</td>
<td class="Rrule" align="center" valign="top">2.4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Psychiatric<br>
</td>
<td class="Rrule" align="center" valign="top">5.7<br>
</td>
<td class="Rrule" align="center" valign="top">8.5<br>
</td>
<td class="Rrule" align="center" valign="top">1.5<br>
</td>
<td class="Rrule" align="center" valign="top">2.9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Other<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">1.8<br>
</td>
<td class="Rrule" align="center" valign="top">1.9<br>
</td>
<td class="Rrule" align="center" valign="top">0.9<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Total<br>
</td>
<td class="Rrule" align="center" valign="top">2.4<br>
</td>
<td class="Rrule" align="center" valign="top">4.3<br>
</td>
<td class="Rrule" align="center" valign="top">1.8<br>
</td>
<td class="Rrule" align="center" valign="top">1.9<br>
</td>
</tr>
</tbody>
</table>
<br><p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.</p>
<br><p>Anyone considering prescribing gabapentin or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p>
<br><p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age)</h2>
<p class="First">Gabapentin use in pediatric patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> 3 to 12 years of age is associated with the occurrence of central nervous system related adverse reactions. The most significant of these can be classified into the following categories: 1) <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> (primarily behavioral problems), 2) <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, including <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behaviors</span>, 3) thought disorder, including concentration problems and change in school performance, and 4) <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span> (primarily <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>). Among the gabapentin-treated patients, most of the reactions were mild to moderate in intensity.<br><br>In controlled clinical <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials in pediatric patients 3 to 12 years of age, the incidence of these adverse reactions was: <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> 6% (gabapentin-treated patients) vs. 1.3% (placebo-treated patients); <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> 5.2% vs. 1.3%; <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span> 4.7% vs. 2.9%; and thought disorder 1.7% vs. 0%. One of these reactions, a report of <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, was considered serious. Discontinuation of gabapentin treatment occurred in 1.3% of patients reporting <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> and <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span> and 0.9% of gabapentin-treated patients reporting <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> and thought disorder. One placebo-treated patient (0.4%) withdrew due to <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Tumorigenic Potential</h2>
<p class="First">In an oral carcinogenicity study, gabapentin increased the incidence of pancreatic acinar cell tumors in rats <span class="Italics">[see <a href="#Section_13.1">Nonclinical Toxicology (13.1)</a>]</span>. The clinical significance of this finding is unknown. Clinical experience during gabapentin’s premarketing development provides no direct means to assess its potential for inducing tumors in humans.<br><br>In clinical studies in adjunctive therapy in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> comprising 2085 patient-years of exposure in patients &gt;12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin’s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, 1 endometrial carcinoma <span class="Italics">in situ</span>), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin. Without knowledge of the background incidence and recurrence in a similar population not treated with gabapentin, it is impossible to know whether the incidence seen in this cohort is or is not affected by treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Sudden and Unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in Patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">During the course of premarketing development of gabapentin, 8 sudden and unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were recorded among a cohort of 2203 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> patients treated (2103 patient-years of exposure) with gabapentin.<br><br>Some of these could represent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in which the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> was not observed, e.g., at night. This represents an incidence of 0.0038 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> not receiving gabapentin (ranging from 0.0005 for the general population of epileptics to 0.003 for a clinical trial population similar to that in the gabapentin program, to 0.005 for patients with refractory <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>). Consequently, whether these figures are reassuring or raise further concern depends on comparability of the populations reported upon to the gabapentin cohort and the accuracy of the estimates provided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections: </p>
<ul class="Disc">
<li>Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>/Sedation and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Withdrawal Precipitated <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status Epilepticus</span> <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li>Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age) <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li>Sudden and Unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in Patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> [<span class="Italics">see </span><span class="Italics"><span class="Italics"><a href="#Section_5.8">Warnings and Precautions (5.8)</a></span>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<br><p><span class="Bold"><span class="Underline">Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></span></span></p>
<p>The most common adverse reactions associated with the use of gabapentin in adults, not seen at an equivalent frequency among placebo-treated patients, were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
<br><p>In the 2 controlled trials in postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, 16% of the 336 patients who received gabapentin and 9% of the 227 patients who received placebo discontinued treatment because of an adverse reaction. The adverse reactions that most frequently led to withdrawal in gabapentin-treated patients were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<br><p>Table 3 lists adverse reactions that occurred in at least 1% of gabapentin-treated patients with postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> participating in placebo-controlled trials and that were numerically more frequent in the gabapentin group than in the placebo group. </p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>TABLE 3. Adverse Reactions in Placebo-Controlled Trials in Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span> 
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Body System/<br>Adverse Reaction<br>
</td>
<td class="Rrule" align="center" valign="top">Gabapentin<br>N=336<br>%<br>
</td>
<td class="Rrule" align="center" valign="top">Placebo<br>N=227<br>%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Body as a Whole</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span><br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Digestive System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Metabolic and Nutritional Disorders</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span><br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Nervous System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</td>
<td class="Rrule" align="center" valign="top">28<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td class="Rrule" align="center" valign="top">21<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Respiratory System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Special Senses</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span><span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="3" valign="top">
<span class="Sup">a</span>  Reported as <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span><br>
</td></tr>
</tbody>
</table>
<br><p>Other reactions in more than 1% of patients but equally or more frequent in the placebo group included <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>.</p>
<br><p>There were no clinically important differences between men and women in the types and incidence of adverse reactions. Because there were few patients whose race was reported as other than white, there are insufficient data to support a statement regarding the distribution of adverse reactions by race.</p>
<br><p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> (Adjunctive Therapy)</span></span></p>
<p>The most common adverse reactions associated with the use of gabapentin in combination with other antiepileptic drugs in patients &gt;12 years of age, not seen at an equivalent frequency among placebo-treated patients, were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>. <br><br>The most common adverse reactions reported with the use of gabapentin in combination with other antiepileptic drugs in pediatric patients 3 to 12 years of age, not seen at an equal frequency among placebo-treated patients, were <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
<br><p>Approximately 7% of the 2074 patients &gt;12 years of age and approximately 7% of the 449 pediatric patients 3 to 12 years of age who received gabapentin in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with withdrawal in patients &gt;12 years of age were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1.2%), <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (0.8%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (0.6%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.6%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.6%). The adverse reactions most commonly associated with withdrawal in pediatric patients were <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> (1.6%), <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> (1.3%), and <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span> (1.1%).</p>
<p>Table 4 lists adverse reactions that occurred in at least 1% of gabapentin-treated patients &gt;12 years of age with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> participating in placebo-controlled trials and were numerically more common in the gabapentin group. In these studies, either gabapentin or placebo was added to the patient’s current antiepileptic drug therapy.</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>TABLE 4. Adverse Reactions in Pooled Placebo-Controlled Add-On Trials In <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Patients &gt;12 years of age 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a</span> Plus background antiepileptic drug therapy<br><span class="Sup">b</span> <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span> was often described as <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. </td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Body System/<br>Adverse Reaction<br>
</td>
<td class="Rrule" align="center" valign="top">Gabapentin<span class="Sup">a</span><br>N=543<br>%<br>
</td>
<td class="Rrule" align="center" valign="top">Placebo<span class="Sup">a</span><br>N=378<br>%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Body As A Whole</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Cardiovascular</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Digestive System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span> or Throat<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Dental Abnormalities<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Nervous System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span><br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span><br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span><br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">Dysarthria</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Abnormal Coordination<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Respiratory System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Skin and Appendages</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">Abrasion</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Urogenital System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Special Senses</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span><span class="Sup">b</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
</tbody>
</table>
<p>Among the adverse reactions occurring at an incidence of at least 10% in gabapentin-treated patients, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> appeared to exhibit a positive dose-response relationship.</p>
<br><p>The overall incidence of adverse reactions and the types of adverse reactions seen were similar among men and women treated with gabapentin. The incidence of adverse reactions increased slightly with increasing age in patients treated with either gabapentin or placebo. Because only 3% of patients (28/921) in placebo-controlled studies were identified as nonwhite (black or other), there are insufficient data to support a statement regarding the distribution of adverse reactions by race.</p>
<br><p>Table 5 lists adverse reactions that occurred in at least 2% of gabapentin-treated patients, age 3 to 12 years of age with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> participating in placebo-controlled trials, and which were numerically more common in the gabapentin group.</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>TABLE 5. Adverse Reactions in a Placebo-Controlled Add-On Trial in Pediatric <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Patients Age 3 to 12 Years 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a</span> Plus background antiepileptic drug therapy </td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Body System/<br>Adverse Reaction<br>
</td>
<td class="Rrule" align="center" valign="top">Gabapentin<span class="Sup">a</span><br>N=119<br>%<br>
</td>
<td class="Rrule" align="center" valign="top">Placebo<span class="Sup">a</span><br>N=128<br>%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Body As A Whole</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infection</span><br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Digestive System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Nervous System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span><br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Underline">Respiratory System</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Infection</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
</tbody>
</table>
<p>Other reactions in more than 2% of pediatric patients 3 to 12 years of age but equally or more frequent in the placebo group included: <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, and <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postmarketing use of gabapentin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br><br>Hepatobiliary disorders: <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span><br>Investigations: blood glucose fluctuation, elevated creatine kinase, elevated liver function tests<br>Metabolism and nutrition disorders: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span><br><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span><br>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span><br>Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>: <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span><br>Skin and subcutaneous tissue disorders: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.<br><br>Adverse reactions following the abrupt discontinuation of gabapentin have also been reported. The most frequently reported reactions were <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Other Antiepileptic Drugs</h2>
<p class="First">Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Hydrocodone</h2>
<p class="First">Coadministration of gabapentin (125 to 500 mg) decreases hydrocodone C<span class="Sub">max</span> and AUC values in a dose-dependent manner. The C<span class="Sub">max</span> and AUC values are 3% to 4% lower, respectively, after administration of 125 mg gabapentin and 21% to 22% lower, respectively, after administration of 500 mg gabapentin. Hydrocodone increases gabapentin AUC values by 14% <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Morphine</h2>
<p class="First">A literature article reported that when a 60 mg controlled-release morphine capsule was administered 2 hours prior to a 600 mg gabapentin capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine <span class="Italics">[see <a href="#Section_16">Patient Counseling Information (17)</a>]</span>. Morphine pharmacokinetic parameter values were not affected by administration of gabapentin 2 hours after morphine. The magnitude of interaction at other doses is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 MAALOX (aluminum hydroxide, magnesium hydroxide)</h2>
<p class="First">The mean bioavailability of gabapentin was reduced by about 20% with concomitant use of an antacid (Maalox<span class="Bold"><span class="Sup">®</span></span>) containing magnesium and aluminum hydroxides.  It is recommended that gabapentin be taken at least 2 hours following Maalox administration <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Drug/Laboratory Test Interactions</h2>
<p class="First">Because false positive readings were reported with the Ames N-Multistix SG<span class="Bold"><span class="Sup">® </span></span>dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic Effects<br></span><br><span class="Underline">Pregnancy Category C:</span> There are no adequate and well-controlled studies in pregnant women. In nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic when administered to pregnant animals at doses similar to or lower than those used clinically. Gabapentin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br><br>When pregnant mice received oral doses of gabapentin (500, 1000, or 3000 mg/kg/day) during the period of organogenesis, embryo-fetal toxicity (increased incidences of skeletal variations) was observed at the two highest doses. The no-effect dose for embryo-fetal developmental toxicity in mice was 500 mg/kg/day or approximately ½ of the maximum recommended human dose (MRHD) of 3600 mg/kg on a body surface area (mg/m<span class="Sup">2</span>) basis.<br><br>In studies in which rats received oral doses of gabapentin (500 to 2000 mg/kg/day), during pregnancy, adverse effect on offspring development (increased incidences of <span class="product-label-link" type="condition" conceptid="194408" conceptname="Hydroureter">hydroureter</span> and/or <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>) were observed at all doses. The lowest effect dose for developmental toxicity in rats is approximately equal to the MRHD on a mg/m<span class="Sup">2</span> basis.<br><br>When pregnant rabbits were treated with gabapentin during the period of organogenesis, an increase in embryo-fetal mortality was observed at all doses tested (60, 300, or 1500 mg/kg). The lowest effect dose for embryo-fetal developmental toxicity in rabbits is less than the MRHD on a mg/m<span class="Sup">2</span> basis.<br><br>In a published study, gabapentin (400 mg/kg/day) was administered by intraperitoneal injection to neonatal mice during the first postnatal week, a period of synaptogenesis in rodents (corresponding to the last trimester of pregnancy in humans). Gabapentin caused a marked decrease in neuronal synapse formation in brains of intact mice and abnormal neuronal synapse formation in a mouse model of synaptic repair. Gabapentin has been shown <span class="Italics">in vitro </span>to interfere with activity of the α2δ subunit of voltage-activated calcium channels, a receptor involved in neuronal synaptogenesis. The clinical significance of these findings is unknown.<br><br>To provide information regarding the effects of <span class="Italics">in utero </span>exposure to gabapentin, physicians are advised to recommend that pregnant patients taking gabapentin enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website <span class="Underline">http://www.aedpregnancyregistry.org/.</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Gabapentin is secreted into human milk following oral administration. A nursed infant could be exposed to a maximum dose of approximately 1 mg/kg/day of gabapentin. Because the effect on the nursing infant is unknown, gabapentin should be used in women who are nursing only if the benefits clearly outweigh the risks.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of gabapentin in the management of postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> in pediatric patients have not been established.<br><br>Effectiveness as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> in pediatric patients below the age of 3 years has not been established <span class="Italics">[see <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The total number of patients treated with gabapentin in controlled clinical trials in patients with postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> was 336, of which 102 (30%) were 65 to 74 years of age, and 168 (50%) were 75 years of age and older. There was a larger treatment effect in patients 75 years of age and older compared with younger patients who received the same dosage. Since gabapentin is almost exclusively eliminated by renal excretion, the larger treatment effect observed in patients ≥75 years may be a consequence of increased gabapentin exposure for a given dose that results from an age-related decrease in renal function. However, other factors cannot be excluded. The types and incidence of adverse reactions were similar across age groups except for <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, which tended to increase in incidence with age.<br><br>Clinical studies of gabapentin in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.<br><br>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.4</a>),<a href="#Section_6">Adverse Reactions (6)</a>, and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage adjustment in adult patients with compromised renal function is necessary <span class="Italics">[see <a href="#Section_2.3">Dosage and Administration (2.3)</a> and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>. Pediatric patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have not been studied.<br><br>Dosage adjustment in patients undergoing hemodialysis is necessary <span class="Italics">[see <a href="#Section_2.3">Dosage and Administration (2.3)</a> and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="Section_9"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="Section_9.1"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Gabapentin is not a scheduled drug.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="Section_9.2"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Gabapentin does not exhibit affinity for benzodiazepine, opiate (mu, delta or kappa), or cannabinoid 1 receptor sites. A small number of postmarketing cases report gabapentin misuse and abuse. These individuals were taking higher than recommended doses of gabapentin for unapproved uses. Most of the individuals described in these reports had a history of poly-<span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> or used gabapentin to relieve symptoms of withdrawal from other substances. When prescribing gabapentin carefully evaluate patients for a history of drug abuse and observe them for signs and symptoms of gabapentin misuse or abuse (e.g., development of tolerance, self-dose escalation, and drug-seeking behavior).</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="Section_9.3"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">There are rare postmarketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved. Such symptoms included <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> after suddenly discontinuing gabapentin that resolved after restarting gabapentin. Most of these individuals had a history of poly-<span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> or used gabapentin to relieve symptoms of withdrawal from other substances. The <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and abuse potential of gabapentin has not been evaluated in human studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">A lethal dose of gabapentin was not identified in mice and rats receiving single oral doses as high as 8000 mg/kg. Signs of acute toxicity in animals included <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, labored breathing, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, sedation, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, or excitation.<br><br>Acute oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of gabapentin up to 49 grams have been reported. In these cases, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, were observed. All patients recovered with supportive care.<br><br>Gabapentin can be removed by hemodialysis. Although hemodialysis has not been performed in the few <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases reported, it may be indicated by the patient’s clinical state or in patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.<br><br>If overexposure occurs, call your poison control center at 1-800-222-1222.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active ingredient in gabapentin tablets, USP is gabapentin, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid.<br><br>The molecular formula of gabapentin is C<span class="Sub">9</span>H<span class="Sub">17</span>NO<span class="Sub">2</span> and the molecular weight is 171.24. The structural formula of gabapentin is:</p>
<br><div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a&amp;name=gabapentin-str.jpg"></div>
<p>Gabapentin USP is a white to off-white crystalline solid with a pK<span class="Sub">a1</span> of 3.7 and a pK<span class="Sub">a2</span> of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is –1.25.<br><br>Each film-coated gabapentin tablet contains 600 mg or 800 mg of gabapentin USP and the following inactive ingredients: <span><a name="OLE_LINK1"></a>copovidone</span>, corn starch, crospovidone, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The precise mechanisms by which gabapentin produces its analgesic and antiepileptic actions are unknown. Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, or degradation. <span class="Italics">In vitro</span> studies have shown that gabapentin binds with high-affinity to the α2δ subunit of voltage-activated calcium channels; however, the relationship of this binding to the therapeutic effects of gabapentin is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">All pharmacological actions following gabapentin administration are due to the activity of the parent compound; gabapentin is not appreciably metabolized in humans.<br><br><span class="Underline">Oral Bioavailability<br></span><br>Gabapentin bioavailability is not dose proportional; i.e., as dose is increased, bioavailability decreases. Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively. Food has only a slight effect on the rate and extent of absorption of gabapentin (14% increase in AUC and C<span class="Sub">max</span>).<br><br><span class="Underline">Distribution<br></span><br>Less than 3% of gabapentin circulates bound to plasma protein. The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD). In patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, steady-state predose (C<span class="Sub">min</span>) concentrations of gabapentin in cerebrospinal fluid were approximately 20% of the corresponding plasma concentrations.<br><br><span class="Underline">Elimination<br></span><br>Gabapentin is eliminated from the systemic circulation by renal excretion as unchanged drug. Gabapentin is not appreciably metabolized in humans.<br><br>Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing. Gabapentin elimination rate constant, plasma clearance, and renal clearance are directly proportional to creatinine clearance. In elderly patients, and in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, gabapentin plasma clearance is reduced. Gabapentin can be removed from plasma by hemodialysis.<br><br><span class="Underline">Special Populations<br></span><span class="Underline"><br></span><span class="Italics">Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br></span><br>Subjects (N=60) with renal impairment (mean creatinine clearance ranging from 13 to 114 mL/min) were administered single 400 mg oral doses of gabapentin. The mean gabapentin half-life ranged from about 6.5 hours (patients with creatinine clearance &gt;60 mL/min) to 52 hours (creatinine clearance &lt;30 mL/min) and gabapentin renal clearance from about 90 mL/min (&gt;60 mL/min group) to about 10 mL/min (&lt;30 mL/min). Mean plasma clearance (CL/F) decreased from approximately 190 mL/min to 20 mL/min <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.4)</a> and <a href="#Section_8.6">Use in Specific Populations (8.6)</a>]</span>. Pediatric patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have not been studied.<br><br><span class="Italics">Hemodialysis</span><br><br>In a study in anuric adult subjects (N=11), the apparent elimination half-life of gabapentin on nondialysis days was about 132 hours; during dialysis the apparent half-life of gabapentin was reduced to 3.8 hours. Hemodialysis thus has a significant effect on gabapentin elimination in anuric subjects <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.4)</a> and <a href="#Section_8.6">Use in Specific Populations (8.6)</a>]</span>.<br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></span><br><span class="Underline"><br></span>Because gabapentin is not metabolized, no study was performed in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.<br><span class="Underline"><br></span><span class="Italics">Age</span><br><br>The effect of age was studied in subjects 20 to 80 years of age. Apparent oral clearance (CL/F) of gabapentin decreased as age increased, from about 225 mL/min in those under 30 years of age to about 125 mL/min in those over 70 years of age. Renal clearance (CLr) and CLr adjusted for body surface area also declined with age; however, the decline in the renal clearance of gabapentin with age can largely be explained by the decline in renal function. <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.4)</a> and <a href="#Section_8.5">Use in Specific Populations (8.5)</a>].<br></span><span class="Underline"><br></span><span class="Italics">Pediatric</span><br><br>Gabapentin pharmacokinetics were determined in 48 pediatric subjects between the ages of 1 month and 12 years following a dose of approximately 10 mg/kg. Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose. In general, pediatric subjects between 1 month and &lt;5 years of age achieved approximately 30% lower exposure (AUC) than that observed in those 5 years of age and older. Accordingly, oral clearance normalized per body weight was higher in the younger children. Apparent oral clearance of gabapentin was directly proportional to creatinine clearance. Gabapentin elimination half-life averaged 4.7 hours and was similar across the age groups studied.<br><br>A population pharmacokinetic analysis was performed in 253 pediatric subjects between 1 month and 13 years of age. Patients received 10 to 65 mg/kg/day given three times a day. Apparent oral clearance (CL/F) was directly proportional to creatinine clearance and this relationship was similar following a single dose and at steady state. Higher oral clearance values were observed in children &lt;5 years of age compared to those observed in children 5 years of age and older, when normalized per body weight. The clearance was highly variable in infants &lt;1 year of age. The normalized CL/F values observed in pediatric patients 5 years of age and older were consistent with values observed in adults after a single dose. The oral volume of distribution normalized per body weight was constant across the age range.<br><br>These pharmacokinetic data indicate that the effective daily dose in pediatric patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> ages 3 and 4 years should be 40 mg/kg/day to achieve average plasma concentrations similar to those achieved in patients 5 years of age and older receiving gabapentin at 30 mg/kg/day <span class="Italics">[see <a href="#Section_2.3">Dosage and Administration (2.3)</a>]</span>.<br><span class="Underline"><br></span><span class="Italics">Gender</span><br><br>Although no formal study has been conducted to compare the pharmacokinetics of gabapentin in men and women, it appears that the pharmacokinetic parameters for males and females are similar and there are no significant gender differences.<br><br><span class="Italics">Race</span><br><br>Pharmacokinetic differences due to race have not been studied. Because gabapentin is primarily renally excreted and there are no important racial differences in creatinine clearance, pharmacokinetic differences due to race are not expected.<br><span class="Underline"><br>Drug Interactions<br></span><span class="Italics"><br>In Vitro Studies<br></span><span class="Italics"><br>In vitro </span>studies were conducted to investigate the potential of gabapentin to inhibit the major cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) that mediate drug and xenobiotic metabolism using isoform selective marker substrates and human liver microsomal preparations. Only at the highest concentration tested (171 mcg/mL; 1 mM) was a slight degree of inhibition (14% to 30%) of isoform CYP2A6 observed. No inhibition of any of the other isoforms tested was observed at gabapentin concentrations up to 171 mcg/mL (approximately 15 times the C<span class="Sub">max</span> at 3600 mg/day).<br><span class="Italics"><br>In Vivo Studies<br></span><br>The drug interaction data described in this section were obtained from studies involving healthy adults and adult patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.<br><span class="Italics"><span class="Underline"><br>Phenytoin<br></span></span><br>In a single (400 mg) and multiple dose (400 mg three times a day) study of gabapentin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.<br><span class="Italics"><span class="Underline"><br>Carbamazepine<br></span></span><br>Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg three times a day; N=12) administration. Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.<br><span class="Italics"><span class="Underline"><br>Valproic Acid<br></span></span><br>The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg three times a day; N=17) were not different and neither were gabapentin pharmacokinetic parameters affected by valproic acid.<br><span class="Italics"><span class="Underline"><br>Phenobarbital<br></span></span><br>Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg three times a day; N=12) are identical whether the drugs are administered alone or together.<br><span class="Italics"><span class="Underline"><br>Naproxen<br></span></span><br>Coadministration (N=18) of naproxen sodium capsules (250 mg) with gabapentin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%. Gabapentin had no effect on naproxen pharmacokinetic parameters. These doses are lower than the therapeutic doses for both drugs. The magnitude of interaction within the recommended dose ranges of either drug is not known.<br><span class="Italics"><span class="Underline"><br>Hydrocodone<br></span></span><br>Coadministration of gabapentin (125 to 500 mg; N=48) decreases hydrocodone (10 mg; N=50) C<span class="Sub">max</span> and AUC values in a dose-dependent manner relative to administration of hydrocodone alone; C<span class="Sub">max</span> and AUC values are 3% to 4% lower, respectively, after administration of 125 mg gabapentin and 21% to 22% lower, respectively, after administration of 500 mg gabapentin. The mechanism for this interaction is unknown. Hydrocodone increases gabapentin AUC values by 14%. The magnitude of interaction at other doses is not known.<br><span class="Italics"><span class="Underline"><br>Morphine<br></span></span><br>A literature article reported that when a 60 mg controlled-release morphine capsule was administered 2 hours prior to a 600 mg gabapentin capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine. Morphine pharmacokinetic parameter values were not affected by administration of gabapentin 2 hours after morphine. The magnitude of interaction at other doses is not known.<br><span class="Italics"><span class="Underline"><br>Cimetidine<br></span></span><br>In the presence of cimetidine at 300 mg QID (N=12), the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%. Thus, cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function. This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance. The effect of gabapentin on cimetidine was not evaluated.<br><span class="Italics"><span class="Underline"><br>Oral Contraceptive<br></span></span><br>Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg three times a day; N=13). The C<span class="Sub">max</span> of norethindrone was 13% higher when it was coadministered with gabapentin; this interaction is not expected to be of clinical importance.<br><span class="Underline"><br></span><span class="Italics"><span class="Underline">Antacid (Maalox<span class="Sup">®</span>)</span> (aluminum hydroxide, magnesium hydroxide)<br></span><br>Antacid (Maalox<span class="Italics"><span class="Underline"><span class="Sup">®</span></span></span>) containing magnesium and aluminum hydroxides reduced the mean bioavailability of gabapentin (N=16) by about 20%. This decrease in bioavailability was about 10% when gabapentin was administered 2 hours after Maalox.<br><span class="Italics"><span class="Underline"><br>Probenecid<br></span></span><br>Probenecid is a blocker of renal tubular secretion. Gabapentin pharmacokinetic parameters without and with probenecid were comparable. This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Gabapentin was administered orally to mice and rats in 2-year carcinogenicity studies. No evidence of drug-related carcinogenicity was observed in mice treated at doses up to 2000 mg/kg/day. At 2000 mg/kg, the plasma gabapentin exposure (AUC) in mice is approximately 2 times that in humans at the MRHD of 3600 mg/day. In rats, increases in the incidence of pancreatic acinar cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> and carcinoma were found in male rats receiving the highest dose (2000 mg/kg), but not at doses of 250 or 1000 mg/kg/day. At 1000 mg/kg, the plasma gabapentin exposure (AUC) in rats is approximately 5 times that in humans at the MRHD.<br><br>Studies designed to investigate the mechanism of gabapentin-induced pancreatic carcinogenesis in rats indicate that gabapentin stimulates DNA synthesis in rat pancreatic acinar cells <span class="Italics">in vitro </span>and, thus, may be acting as a tumor promoter by enhancing mitogenic activity. It is not known whether gabapentin has the ability to increase cell proliferation in other cell types or in other species, including humans.<br><br>Gabapentin did not demonstrate mutagenic or genotoxic potential in three <span class="Italics">in vitro </span>and four <span class="Italics">in vivo </span>assays. It was negative in the Ames test and the <span class="Italics">in vitro </span>HGPRT forward mutation assay in Chinese hamster lung cells; it did not produce significant increases in chromosomal aberrations in the <span class="Italics">in vitro </span>Chinese hamster lung cell assay; it was negative in the <span class="Italics">in vivo </span>chromosomal aberration assay and in the <span class="Italics">in vivo </span>micronucleus test in Chinese hamster bone marrow; it was negative in the <span class="Italics">in vivo </span>mouse micronucleus assay; and it did not induce unscheduled DNA synthesis in hepatocytes from rats given gabapentin.<br><br>No adverse effects on fertility or reproduction were observed in rats at doses up to 2000 mg/kg. At 2000 mg/kg, the plasma gabapentin exposure (AUC) in rats is approximately 8 times that in humans at the MRHD.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></h2>
<p class="First">Gabapentin was evaluated for the management of postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> (PHN) in two randomized, double-blind, placebo-controlled, multicenter studies. The intent-to-treat (ITT) population consisted of a total of 563 patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> for more than 3 months after healing of the <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> (Table 6).</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span> TABLE 6. Controlled PHN Studies: Duration, Dosages, and Number of Patients 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span> Given in 3 divided doses (TID) </td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Study<br>
</td>
<td class="Rrule" align="center" valign="top">Study<br>Duration<br>
</td>
<td class="Rrule" align="center" valign="top">Gabapentin<br>(mg/day)<span class="Sup">a</span><br>Target Dose<br>
</td>
<td class="Rrule" align="center" valign="top">Patients <br>Receiving <br>Gabapentin<br>
</td>
<td class="Rrule" align="center" valign="top">Patients <br>Receiving <br>Placebo<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">8 weeks<br>
</td>
<td class="Rrule" align="center" valign="top">3600<br>
</td>
<td class="Rrule" align="center" valign="top">113<br>
</td>
<td class="Rrule" align="center" valign="top">116<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">7 weeks<br>
</td>
<td class="Rrule" align="center" valign="top">1800, 2400<br>
</td>
<td class="Rrule" align="center" valign="top">223<br>
</td>
<td class="Rrule" align="center" valign="top">111<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="right" colspan="3" valign="top">Total<br>
</td>
<td class="Rrule" align="center" valign="top">336<br>
</td>
<td class="Rrule" align="center" valign="top">227<br>
</td>
</tr>
</tbody>
</table>
<p>Each study included a 7- or 8-week double-blind phase (3 or 4 weeks of titration and 4 weeks of fixed dose). Patients initiated treatment with titration to a maximum of 900 mg/day gabapentin over 3 days. Dosages were then to be titrated in 600 to 1200 mg/day increments at 3- to 7-day intervals to the target dose over 3 to 4 weeks. Patients recorded their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in a daily diary using an 11-point numeric <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rating scale ranging from 0 (no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) to 10 (worst possible <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>). A mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score during baseline of at least 4 was required for randomization. Analyses were conducted using the ITT population (all randomized patients who received at least one dose of study medication).</p>
<br><p>Both studies demonstrated efficacy compared to placebo at all doses tested.</p>
<br><p>The reduction in weekly mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores was seen by Week 1 in both studies, and were maintained to the end of treatment. Comparable treatment effects were observed in all active treatment arms. Pharmacokinetic/pharmacodynamic modeling provided confirmatory evidence of efficacy across all doses. Figures 1 and 2 show <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scores over time for Studies 1 and 2.</p>
<br><div class="Figure"><img alt="Figure 1. Weekly Mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Scores (Observed Cases in ITT Population): Study 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a&amp;name=gabapentin-fig2.jpg"></div>
<br><div class="Figure"><img alt="Figure 2. Weekly Mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Scores (Observed Cases in ITT Population): Study 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a&amp;name=gabapentin-fig3.jpg"></div>
<br><p>The proportion of responders (those patients reporting at least 50% improvement in endpoint <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score compared with baseline) was calculated for each study (Figure 3).</p>
<br><div class="Figure"><img alt="Figure 3. Proportion of Responders (patients with ≥50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score) at Endpoint: Controlled PHN Studies" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a&amp;name=gabapentin-fig4.jpg"></div>
<p>Figure 3. Proportion of Responders (patients with ≥50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score) at Endpoint: Controlled PHN Studies</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-14.2"></a><p></p>
<h2>14. 2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> for Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> (Adjunctive Therapy)</h2>
<p class="First">The effectiveness of gabapentin as adjunctive therapy (added to other antiepileptic drugs) was established in multicenter placebo-controlled, double-blind, parallel-group clinical trials in adult and pediatric patients (3 years and older) with refractory <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span>.<br><br>Evidence of effectiveness was obtained in three trials conducted in 705 patients (age 12 years and above) and one trial conducted in 247 pediatric patients (3 to 12 years of age). The patients enrolled had a history of at least 4 <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> per month in spite of receiving one or more antiepileptic drugs at therapeutic levels and were observed on their established antiepileptic drug regimen during a 12-week baseline period (6 weeks in the study of pediatric patients). In patients continuing to have at least 2 (or 4 in some studies) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per month, gabapentin or placebo was then added on to the existing therapy during a 12-week treatment period. Effectiveness was assessed primarily on the basis of the percent of patients with a 50% or greater reduction in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency from baseline to treatment (the “responder rate?) and a derived measure called response ratio, a measure of change defined as (T -B)/(T + B), in which B is the patient’s baseline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency and T is the patient’s <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency during treatment. Response ratio is distributed within the range -1 to +1. A zero value indicates no change while complete elimination of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> would give a value of -1; increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates would give positive values. A response ratio of -0.33 corresponds to a 50% reduction in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency. The results given below are for all <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> in the intent-to-treat (all patients who received any doses of treatment) population in each study, unless otherwise indicated.<br><br>One study compared gabapentin 1200 mg/day, in three divided doses, with placebo. Responder rate was 23% (14/61) in the gabapentin group and 9% (6/66) in the placebo group; the difference between groups was statistically significant. Response ratio was also better in the gabapentin group (-0.199) than in the placebo group (-0.044), a difference that also achieved statistical significance.<br><br>A second study compared primarily gabapentin 1200 mg/day, in three divided doses (N=101), with placebo (N=98). Additional smaller gabapentin dosage groups (600 mg/day, N=53; 1800 mg/day, N=54) were also studied for information regarding dose response. Responder rate was higher in the gabapentin 1200 mg/day group (16%) than in the placebo group (8%), but the difference was not statistically significant. The responder rate at 600 mg (17%) was also not significantly higher than in the placebo, but the responder rate in the 1800 mg group (26%) was statistically significantly superior to the placebo rate. Response ratio was better in the gabapentin 1200 mg/day group (-0.103) than in the placebo group (-0.022); but this difference was also not statistically significant (p = 0.224). A better response was seen in the gabapentin 600 mg/day group (-0.105) and 1800 mg/day group (-0.222) than in the 1200 mg/day group, with the 1800 mg/day group achieving statistical significance compared to the placebo group.<br><br>A third study compared gabapentin 900 mg/day, in three divided doses (N=111), and placebo (N=109). An additional gabapentin 1200 mg/day dosage group (N=52) provided dose-response data. A statistically significant difference in responder rate was seen in the gabapentin 900 mg/day group (22%) compared to that in the placebo group (10%). Response ratio was also statistically significantly superior in the gabapentin 900 mg/day group (-0.119) compared to that in the placebo group (-0.027), as was response ratio in 1200 mg/day gabapentin (-0.184) compared to placebo.<br><br>Analyses were also performed in each study to examine the effect of gabapentin on preventing secondarily generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>. Patients who experienced a secondarily generalized tonic-clonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in either the baseline or in the treatment period in all three placebo-controlled studies were included in these analyses. There were several response ratio comparisons that showed a statistically significant advantage for gabapentin compared to placebo and favorable trends for almost all comparisons.<br><br>Analysis of responder rate using combined data from all three studies and all doses (N=162, gabapentin; N=89, placebo) also showed a significant advantage for gabapentin over placebo in reducing the frequency of secondarily generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>.<br><br>In two of the three controlled studies, more than one dose of gabapentin was used. Within each study, the results did not show a consistently increased response to dose. However, looking across studies, a trend toward increasing efficacy with increasing dose is evident (see Figure 4).<br><img alt="Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">Partial Seizures</span>" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a&amp;name=gabapentin-fig5.jpg"><br>Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">Partial Seizures</span><br><br>In the figure, treatment effect magnitude, measured on the Y axis in terms of the difference in the proportion of gabapentin and placebo-assigned patients attaining a 50% or greater reduction in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency from baseline, is plotted against the daily dose of gabapentin administered (X axis).<br><br>Although no formal analysis by gender has been performed, estimates of response (Response Ratio) derived from clinical trials (398 men, 307 women) indicate no important gender differences exist. There was no consistent pattern indicating that age had any effect on the response to gabapentin. There were insufficient numbers of patients of races other than Caucasian to permit a comparison of efficacy among racial groups.<br><br>A fourth study in pediatric patients age 3 to 12 years compared 25 to 35 mg/kg/day gabapentin (N=118) with placebo (N=127). For all <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> in the intent-to-treat population, the response ratio was statistically significantly better for the gabapentin group (-0.146) than for the placebo group (-0.079). For the same population, the responder rate for gabapentin (21%) was not significantly different from placebo (18%).<br><br>A study in pediatric patients age 1 month to 3 years compared 40 mg/kg/day gabapentin (N=38) with placebo (N=38) in patients who were receiving at least one marketed antiepileptic drug and had at least one partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during the screening period (within 2 weeks prior to baseline). Patients had up to 48 hours of baseline and up to 72 hours of double-blind video EEG monitoring to record and count the occurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. There were no statistically significant differences between treatments in either the response ratio or responder rate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Gabapentin Tablets, USP are supplied as follows:<br><span class="Bold"><br>Gabapentin Tablets USP, 600 mg</span> are white, biconvex, elliptical, film-coated tablets, with deep break line on both sides and debossed with ‘D’ and ‘24’ on either side of the break line on one side and plain on other side.<br><br>            Bottles of 100                         NDC 16714-330-01<br>            Bottles of 500                         NDC 16714-330-02<br><span class="Bold"><br>Gabapentin Tablets USP, 800 mg</span> are white, biconvex, elliptical, film-coated tablets, with deep break line on both sides and debossed with ‘D’ and ‘25’ on either side of the break line on one side and plain on other side.<br><br>            Bottles of 100                         NDC 16714-332-01<br>            Bottles of 500                         NDC 16714-332-02<br><span class="Bold"><br>Store at</span> 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_16"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide).<br><span class="Underline"><br>Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span><br></span><br>Prior to initiation of treatment with gabapentin, instruct patients that a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other signs or symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.<br><span class="Underline"><br>Effects on Driving and Operating Heavy Machinery<br></span><br>Inform patients that gabapentin may cause a significant driving impairment. Accordingly, advise them not to drive a car until they have gained sufficient experience on gabapentin to assess whether gabapentin impairs their ability to drive, although patients’ ability to determine their level of impairment can be unreliable. Inform patients that it is not known how long this effect lasts. They should be told the same thing regarding the operation of heavy machinery.<br><span class="Underline"><br><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br><br></span>Advise patients that gabapentin may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and other symptoms and signs of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. Accordingly, advise them neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on gabapentin to gauge whether or not it affects their mental and/or motor performance adversely.<br><span class="Underline"><br>Suicidal Thinking and Behavior<br></span><br>Counsel the patient, their caregivers, and families that AEDs, including gabapentin, may increase the risk of suicidal thoughts and behavior. Advise patients of the need to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Instruct patients to report behaviors of concern immediately to healthcare providers <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>]</span>.<br><span class="Underline"><br>Use in Pregnancy<br></span><br>Instruct patients to notify their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breast feeding or intend to breast feed during therapy <span class="Italics">[see <a href="#Section_8.1">Use in Specific Populations (8.1)</a> and <a href="#Section_8.3">(8.3)</a>]</span>.<br><br>Encourage patients to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 <span class="Italics">[see <a href="#Section_8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Section_30"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">Gabapentin Tablets, USP<br></span><span class="Bold"><br>(<span class="Bold">gab'' a pen' tin</span>)<br></span><br>Read the Medication Guide before you start taking gabapentin tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.<br><span class="Bold"><br>What is the most important information I should know about </span><span class="Bold">gabapentin tablets?<br></span><span class="Bold"><br>Do not stop taking </span><span class="Bold">gabapentin tablets without first talking to your healthcare provider.<br></span>Stopping gabapentin tablets suddenly can cause serious problems.<br><span class="Bold"><br>Gabapentin tablets c</span><span class="Bold">an cause serious side effects including:<br></span><br><span class="Bold">1.  Suicidal Thoughts. Like other antiepileptic drugs, gabapentin tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.<br><br>Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></p>
<ul class="Disc">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions?</span></p>
<ul class="Disc">
<li>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.</li>
<li>Keep all follow-up visits with your healthcare provider as scheduled.</li>
</ul>
<p>Call your healthcare provider between visits as needed, especially if you are worried about symptoms.<br><span class="Bold"><br>Do not stop taking </span><span class="Bold">gabapentin tablets </span><span class="Bold">without first talking to a healthcare provider.</span></p>
<ul class="Disc">
<li>Stopping gabapentin tablets suddenly can cause serious problems. Stopping a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicine suddenly in a patient who has <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that will not stop (<span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>).</li>
<li>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.</li>
</ul>
<p><span class="Bold">2.  Changes in behavior and thinking -</span> Using gabapentin tablets in children 3 to 12 years of age can cause emotional changes, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, problems with concentration, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, changes in school performance, and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>.<br><br><span class="Bold">3.  Gabapentin tablets may cause a serious or life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span></span> that may affect your skin or other parts of your body such as your liver or blood cells. You may or may not have <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> when you get this type of reaction. It may cause you to be hospitalized or to stop gabapentin tablets. Call a healthcare provider right away if you have any of the following symptoms:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen glands</span> that do not go away</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lip and tongue</li>
<li>yellowing of your skin or of the whites of the eyes</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li>unexpected <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></li>
<li>frequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></li>
</ul>
<p>These symptoms may be the first signs of a serious reaction. A healthcare provider should examine you to decide if you should continue taking gabapentin tablets.<br><span class="Bold"><br>What are </span><span class="Bold">gabapentin tablets?<br></span><br>Gabapentin tablets are a prescription medicine used to treat:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> from damaged nerves (postherpetic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) that follows healing of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span> (a painful <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> that comes after a <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) in adults.</li>
<li><span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">Partial seizures</span> when taken together with other medicines in adults and children 3 years of age and older with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</li>
</ul>
<p><span class="Bold">Who should not take </span><span class="Bold">gabapentin tablets?<br></span><br>Do not take gabapentin tablets if you are allergic to gabapentin or any of the other ingredients in gabapentin tablets. See the end of this Medication Guide for a complete list of ingredients in gabapentin tablets.<br><span class="Bold"><br>What should I tell my healthcare provider before taking </span><span class="Bold">gabapentin tablets?<br></span><span class="Bold"><br>Before taking </span><span class="Bold">gabapentin tablets, tell your healthcare provider if you</span>:</p>
<ul class="Disc">
<li>have or have had kidney problems or are on hemodialysis</li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood problems, or suicidal thoughts or behavior</li>
<li>are pregnant or plan to become pregnant. It is not known if gabapentin tablets can harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking gabapentin tablets. You and your healthcare provider will decide if you should take gabapentin tablets while you are pregnant.    <ul class="Disc"><li>If you become pregnant while taking gabapentin tablets, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. You can enroll in this registry by calling 1-888-233-2334.</li></ul>
</li>
<li>are breast-feeding or plan to breast-feed. Gabapentin can pass into breast milk. You and your healthcare provider should decide how you will feed your baby while you take gabapentin tablets. </li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.<br><br>Taking gabapentin tablets with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.<br><br>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.<br><span class="Bold"><br>How should I take </span><span class="Bold">gabapentin tablets?</span></p>
<ul class="Disc">
<li>Take gabapentin tablets exactly as prescribed. Your healthcare provider will tell you how much gabapentin to take.    <ul class="Disc">
<li>Do not change your dose of gabapentin tablets without talking to your healthcare provider.</li>
<li>If you take gabapentin tablets and break a tablet in half, the unused half of the tablet should be taken at your next scheduled dose. Half tablets not used within 28 days of breaking should be thrown away</li>
</ul>
</li>
<li>Gabapentin tablets can be taken with or without food. If you take an antacid containing aluminum and magnesium, such as Maalox<span class="Sup">®</span>, Mylanta<span class="Sup">®</span>, Gelusil<span class="Sup">®</span>, Gaviscon<span class="Sup">®</span>, or Di-Gel<span class="Sup">®</span>, you should wait at least 2 hours before taking your next dose of gabapentin tablets.</li>
</ul>
<p>If you take too much gabapentin, call your healthcare provider or your local Poison Control Center right away at 1-800-222-1222.<br><span class="Bold"><br>What should I avoid while taking </span><span class="Bold">gabapentin tablets?</span></p>
<ul class="Disc">
<li>Do not drink alcohol or take other medicines that make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> or dizzy while taking gabapentin tablets without first talking with your healthcare provider. Taking gabapentin tablets with alcohol or drugs that cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> may make your <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> worse.</li>
<li>Do not drive, operate heavy machinery, or do other dangerous activities until you know how gabapentin tablets affect you. Gabapentin tablets can slow your thinking and motor skills.</li>
</ul>
<p><span class="Bold">What are the possible side effects of </span><span class="Bold">gabapentin tablets?<br></span><span class="Bold"><br>Gabapentin tablets </span><span class="Bold">may cause serious side effects including:<br></span><br>See <span class="Bold">“What is the most important information I should know about gabapentin tablets??</span></p>
<ul class="Disc">
<li>problems driving while using gabapentin tablets. See <span class="Bold">“What should I avoid while taking gabapentin tablets??</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><span class="Bold"></span>
</li>
<li>
<span class="Bold">The most common side effects of </span><span class="Bold">gabapentin tablets i</span><span class="Bold">nclude:</span><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">lack of coordination</span></li>
<li>feeling tired</li>
<li><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>feeling drowsy</li>
<li>jerky movements</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>difficulty with coordination</li>
<li>difficulty with speaking</li>
<li><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></li>
<li>unusual eye movement</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, usually of legs and feet</li>
</ul>
</li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.<br><br>These are not all the possible side effects of gabapentin tablets. For more information, ask your healthcare provider or pharmacist.<br><span class="Bold"><br>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<br></span><span class="Bold"><br>How should I store </span><span class="Bold">gabapentin tablets?</span></p>
<ul class="Disc"><li>Store gabapentin tablets between 20° to 25°C (68° to 77°F).</li></ul>
<p><span class="Bold">Keep </span><span class="Bold">gabapentin tablets and all medicines out of the reach of children.<br></span><span class="Bold"><br>General information about the safe and effective use of </span><span class="Bold">gabapentin tablets<br></span><br>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use gabapentin tablets for a condition for which it was not prescribed. Do not give gabapentin tablets to other people, even if they have the same symptoms that you have. They may harm them.<br><br>This Medication Guide summarizes the most important information about gabapentin tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about gabapentin tablets that was written for healthcare professionals.<br><br>For more information, call Northstar Rx LLC at 1-800-206-7821.<br><span class="Bold"><br>What are the ingredients in </span><span class="Bold">gabapentin tablets?<br></span><span class="Bold"><br>Active ingredient: </span>gabapentin<br><span class="Bold"><br>Inactive ingredients: </span>copovidone, corn starch, crospovidone, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, and talc.<br><br>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br><br>* All brands listed are the trademarks of their respective owners and are not trademarks of Aurobindo Pharma Limited.</p>
<br><p>Manufactured for: Northstar Rx LLC<br>                            Memphis, TN 38141<br>                            Toll Free: 1-800-206-7821<br><br>Manufactured by: Aurobindo Pharma Limited<br>                              Unit-VII (SEZ)<br>                              Mahaboob Nagar (Dt)<br>                              509302, India.<br><br>M.L.No.: 22/MN/AP/2009/F/R<br><br>Revised: 06/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-18"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 600 mg (100 Tablets Bottle)</h1>
<p class="First"><span class="Bold">NDC 16714-330-01                    <span class="Bold">Rx only </span><br>Gabapentin <br>Tablets, USP <br>600 mg <br>PHARMACIST: Dispense the Medication <br>Guide provided separately to each patient. <br>100 Tablets <br>NORTHSTAR<br></span></p>
<br><div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 600 mg (100 Tablets Bottle)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a&amp;name=gabapentin-fig6.jpg"></div>
<br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_31"></a><a name="section-19"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 800 mg (100 Tablets Bottle)</h1>
<p class="First"><span class="Bold">NDC 16714-332-01                     <span class="Bold">Rx only</span>                 <br>Gabapentin <br>Tablets, USP<br>800 mg<br>PHARMACIST: Dispense the Medication <br>Guide provided separately to each patient.<br>100 Tablets<br>NORTHSTAR<br><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 800 mg (100 Tablets Bottle)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a&amp;name=gabapentin-fig7.jpg"><br><br></span></p>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GABAPENTIN 		
					</strong><br><span class="contentTableReg">gabapentin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16714-330</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GABAPENTIN</strong> (GABAPENTIN) </td>
<td class="formItem">GABAPENTIN</td>
<td class="formItem">600 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Elliptical, Biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">D;24</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16714-330-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16714-330-02</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200651</td>
<td class="formItem">10/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GABAPENTIN 		
					</strong><br><span class="contentTableReg">gabapentin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16714-332</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GABAPENTIN</strong> (GABAPENTIN) </td>
<td class="formItem">GABAPENTIN</td>
<td class="formItem">800 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Elliptical, Biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">D;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16714-332-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16714-332-02</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200651</td>
<td class="formItem">10/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>NorthStar Rx LLC
							(830546433)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Aurobindo Pharma Limited (650082092)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">650381903</td>
<td class="formItem">ANALYSIS(16714-330, 16714-332), MANUFACTURE(16714-330, 16714-332)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917647</td>
<td class="formItem">API MANUFACTURE(16714-330, 16714-332)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b987be1f-73ba-433f-a0eb-5029785f5dd7</div>
<div>Set id: 9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a</div>
<div>Version: 4</div>
<div>Effective Time: 20150623</div>
</div>
</div> <div class="DistributorName">NorthStar Rx LLC</div></p>
</body></html>
